Food and Drug Administration Launches 2015 National Safe Drug Use Month
The Food and Drug Administration of all provinces, autonomous regions, and municipalities directly under the Central Government, and the Food and Drug Administration of Xinjiang Production and Construction Corps: According to the requirements of the "National Food and Drug Safety Science Popularization Action Plan (2011-2015)", the "National Safe Drug Month" (Hereinafter referred to as safety month). In order to effectively carry out this year's safety month activities, the relevant matters are hereby notified as follows: the 1. time is arranged from September 1 to October 31, 2015. 2. publicity focuses on publicizing and implementing the "Opinions of the State Council on Reforming the Review and Approval System for Drugs and Medical Devices" (Guo Fa [2015] No. 44
2015-08-26
The cost of using genetically modified yeast to make painkillers in the United States is expected to be reduced by 10 times.
Yeast can be used not only to make steamed bread, but also to make painkillers. Recently, a study published in "Science" introduced a method of using genetically modified yeast to produce morphine-based painkillers. The researchers said that the method can not only shorten the production cycle of drugs from a year to a few days, but also reduce the cost to one tenth of the traditional method. When the technology matures in the future, it is expected to greatly reduce the retail price of related drugs.
Pharmaceutical August 2015 report: focus on the reform of state-owned enterprises in the pharmaceutical industry
The market plunged sharply in July, with all sectors falling sharply. Among them, the relatively small decline is the agriculture, forestry, animal husbandry and fishing, defense and military industry sector, followed by banking, leisure services and mining sector. In July, small-cap stocks fell more, while large-cap stocks fell relatively small. Although the pharmaceutical industry has a certain increase, but in view of China is about to enter an aging society, coupled with the performance support of pharmaceutical stocks, investors are still optimistic about pharmaceutical stocks, so the decline of pharmaceutical stocks is not large. And the pharmaceutical industry may have a good follow-up, investors can still be optimistic about the pharmaceutical industry.
Global pharmaceutical sales will reach $1.3 trillion in 2018
Thomson Reuters annual CMRFactbook pointed out that 46 new molecular entities were approved for listing in developed countries in 2014, which is far higher than the number in any year since 2005. At the same time, 2014 was also a year of outstanding sales, with $1 trillion. The sales of the United States challenged those who had a negative attitude towards the pharmaceutical industry.
New drug development in China: How close are we to the first original drug?
According to a data provided by the Tufts Center for Drug Development Research, the average cost of developing a new drug is about $2.6 billion. In 2013, the R & D investment of the world's top ten pharmaceutical companies accounted for 17.8 percent of sales, up to $60.39 billion, while the R & D investment of the top ten domestic pharmaceutical companies was only 1% of sales, about $0.3 billion.
Antidepressant modafinil, or become the first "smart drug"
Modafinil (Modafinil), as an antidepressant drug for the treatment of sleep disorders such as narcolepsy, was approved by the US Food and Drug Administration (FDA) in 1998. Modafinil became the first marketed drug for the treatment of sleep disorders with good central excitatory effects and fewer side effects. Past studies have found that people who are sleep-deprived take modafinil and their mental state is significantly enhanced. But for normal people, modafinil this effect is not obvious. And modafinil can be used as an auxiliary drug for the treatment of depression to enhance the therapeutic effect. It is precisely because modafinil has
Hot attention: how to improve the current drug bidding procurement system?
The successive introduction of No. 7 and No. 70 has outlined the basic outline of the general direction and rules of regulation and control for the future purchase of drugs in various places. With reference to the above-mentioned basic rules and combined with the actual situation of various regions, it has become a dynamic mode of a new round of online procurement to continuously absorb good local innovation experience and measures for nationwide integration and promotion. Any policy and system has its positive aspects, but also some aspects that may be omitted or need to be further improved. Some thinking suggestions are also put forward from the perspective of industry and enterprises. The fairness, rationality and scientificity of the recruitment catalogue Anhui, Fujian and other places are all based on medical insurance, agricultural cooperation and basic drug products.
About Wuyao
Introduction to Wuyao
Organizational Structure
Enterprise honor
Enterprise culture
Development process
Product display
About Yangxin
Company Introduction
Intermediates/Fine Chemicals
Food Additives
API
News
Company News
Industry News
Media coverage
Network
Business Layout
Domestic customers
Foreign customers
Contact Us
Contact Information
Online message